Hugel Aesthetics Expands U.S. Leadership at 2026 ASDS Annual Meeting with Innovations and Clinical Insights

Hugel Aesthetics Expands Its U.S. Presence at the 2026 ASDS Annual Meeting



In an impressive showcase of growth and innovation, Hugel Aesthetics, a prominent name in the medical aesthetics industry, highlighted its increasing footprint in the U.S. during the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, which took place from November 5-8 in San Diego, California. This event served as a pivotal gathering, attracting top-tier physicians, researchers, and industry stakeholders dedicated to defining the future landscape of aesthetic medicine.

Commitment to Clinical Excellence


As an esteemed partner of the ASDS Industry Advisory Council (IAC), Hugel Aesthetics demonstrated its commitment to advancing dermatologic surgery through research collaboration. During the conference, the company's various teams, including commercial and medical affairs, engaged in meaningful discussions with industry leaders, participated in podcast interviews, and hosted a reception, marking a substantial contribution to the conversation surrounding aesthetic advancements.

CEO Carrie Strom articulated the significance of the ASDS meeting, stating, "This event brings together some of the most influential voices in dermatology and aesthetics, making it an essential platform for scientific collaboration and innovation." Hugel’s engagement at ASDS serves not only as a reflection of its expanding U.S. presence but also its dedication to advancing research that aids medical professionals in making informed treatment choices, ultimately enhancing patient outcomes.

Highlighting Letybo: Clinical Findings and Outcomes


Among the key discussions were the findings from the BLESS clinical program. These analyses, led by the board-certified dermatologist Dr. Michael H. Gold, emphasized the effectiveness of Letybo (letibotulinumtoxinA-wlbg) in treating glabellar lines, commonly known as frown lines. The Phase 3 BLESS III study yielded impressive results, demonstrating that 64.7% of patients receiving Letybo experienced significant improvement within four weeks as opposed to none in the placebo group. Furthermore, patients saw a median onset of improvement within just three days, with no severe treatment-related adverse events reported.

Particularly notable was a post hoc analysis focusing on women aged 35 to 50, showcasing rapid results where 87.4% experienced an improvement by week two. Additionally, 73.6% maintained no visible frown lines by week four. These insights underline the transformative impact Letybo can have on patients' quality of life and emotional well-being, reinforcing Hugel’s commitment to ongoing research and innovation.

A Vision for the Future


Hugel Aesthetics has built a solid reputation since its establishment in 2001, specializing in injectables for skin rejuvenation, including botulinum toxin products, hyaluronic acid fillers, and other aesthetic solutions. The company has expanded its reach to over 70 countries and operates multiple global subsidiaries. As it continues to leverage its industry momentum, Hugel Aesthetics is poised for further growth and innovation in the competitive landscape of medical aesthetics.

This year’s ASDS meeting clearly marked a significant milestone for Hugel Aesthetics as it engages with new markets and drives forward the conversation on aesthetic medicine. As the company amplifies its U.S. presence, the future promises exciting advancements in aesthetic treatments anchored by rigorous clinical research and a commitment to excellence.

For further details on Hugel Aesthetics and their latest innovations, interested parties can visit their official website.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.